ArticleBlood advances2025
A simple and efficient method for the robust expansion of human ILC2s to prevent acute GVHD.
Article in Blood advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Gastrointestinal acute graft versus host disease: a translational perspective from pathogenesis to precision prevention and treatment.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
abstractReconstitution of stem cells and enhancement of the barrier function of the gastrointestinal (GI) tract is critical to the resolution of intestinal acute graft-versus-host disease (aGVHD). Previously, our group has shown in murine models that type 2 innate lymphoid cells (ILC2s) generate proteins in the GI tract that enhanced GI tract barrier function, and diminished the expansion and function of proinflammatory donor cells when given to recipients of allogeneic stem cell transplant. Therefore, the infusion of donor ILC2s could treat or prevent GI tract aGVHD but, for this approach to be clinically applicable, robust expansion of a homogeneous population of human ILC2s is needed. Here, we describe a method for the rapid expansion of a uniform population of human ILC2s that decrease GVHD in NOD scid gamma mice. The addition of interleukin 4 to the culture was critical to prevent the expansion of proinflammatory ILC1-like cells. Our approach should allow for the evaluation of human ILC2 cells to treat therapy-resistant GI tract aGVHD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.